ISA Pharmaceuticals (Netherlands)

Recent papers from ISA Pharmaceuticals (Netherlands)

1. Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trialGynecologic Oncology · 2025
2. Results of a randomized, double-blind, placebo-controlled, phase 2 study (OpcemISA) of the combination of ISA101b and cemiplimab versus cemiplimab for recurrent/metastatic (R/M) HPV16-positive oropharyngeal cancer (OPC).Journal of Clinical Oncology · 2024
3. Combination of cemiplimab and ISA101b vaccine for the treatment of recurrent/metastatic HPV16 cervical cancer.Journal of Clinical Oncology · 2024
4. Delayed vaccine-induced CD8⁺ T cell expansion by topoisomerase I inhibition mediates enhanced CD70-dependent tumor eradicationJournal for ImmunoTherapy of Cancer · 2023
5. Induction of broad multifunctional CD8+ and CD4+ T cells by hepatitis B virus antigen-based synthetic long peptides ex vivoFrontiers in Immunology · 2023
6. Abatacept, Cenicriviroc, or Infliximab for Treatment of Adults Hospitalized With COVID-19 PneumoniaJAMA · 2023
7. Enhanced HPV16 E6/E7+ tumor eradication via induction of tumor-specific T cells by therapeutic vaccination with virosomes presenting synthetic long peptidesCancer Immunology Immunotherapy · 2023
8. Risk of COVID-19 Diagnosis and Hospitalisation in Patients with Osteoarthritis or Back Pain Treated with Ibuprofen Compared to Other NSAIDs or Paracetamol: A Network Cohort StudyDrugs · 2023
9. Intradermal vaccination of HPV-16 E6 synthetic peptides conjugated to an optimized Toll-like receptor 2 ligand shows safety and potent T cell immunogenicity in patients with HPV-16 positive (pre-)malignant lesionsJournal for ImmunoTherapy of Cancer · 2022
10. Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer?Cell Reports Medicine · 2022
11. Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine in children and adolescents 6 months through 17 years of age in IndiaHuman Vaccines & Immunotherapeutics · 2022
12. Peptide emulsions in incomplete Freund’s adjuvant create effective nurseries promoting egress of systemic CD4⁺ and CD8⁺ T cells for immunotherapy of cancerJournal for ImmunoTherapy of Cancer · 2022
13. A third vaccination with a single T cell epitope confers protection in a murine model of SARS-CoV-2 infectionNature Communications · 2022
14. ISA101 and nivolumab for HPV-16⁺ cancer: updated clinical efficacy and immune correlates of responseJournal for ImmunoTherapy of Cancer · 2022
15. IFN‐γ‐induced PD‐L1 expression on human melanocytes is impaired in vitiligoExperimental Dermatology · 2021
16. Special Review: The future of ImmunotherapyImmunotherapy Advances · 2020
17. Targeting the PD-1/PD-L1 Axis in Human VitiligoFrontiers in Immunology · 2020
18. Neutralizing Antibody Responses Induced by HIV-1 Envelope Glycoprotein SOSIP Trimers Derived from Elite NeutralizersJournal of Virology · 2020
19. Combination vaccine based on citrullinated vimentin and enolase peptides induces potent CD4-mediated anti-tumor responsesJournal for ImmunoTherapy of Cancer · 2020
20. Antimicrobial Peptide Omiganan Enhances Interferon Responses to Endosomal Toll‐Like Receptor Ligands in Human Peripheral Blood Mononuclear CellsClinical and Translational Science · 2020